{
    "clinical_study": {
        "@rank": "127773", 
        "arm_group": {
            "arm_group_label": "GlucoTab System", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Objective: To investigate the performance (safety) of the GlucoTab system for glycaemic\n      management in non-critically ill patients with type 2 diabetes at general wards."
        }, 
        "brief_title": "Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained after being advised of the nature of the study\n\n          -  Male or female aged \u226518 years\n\n          -  Type 2 diabetes (treated with diet, oral agents, non-insulin injected anti-diabetic\n             medicine, insulin therapy or any combination of the four) or newly diagnosed\n             hyperglycaemia which requires s.c. insulin therapy\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes, gestational diabetes\n\n          -  Any disease or condition which the investigator or treating physician feels would\n             interfere with the trial or the safety of the patient\n\n          -  Pregnancy\n\n          -  Any mental condition rendering the patient incapable of giving his consent\n\n          -  Known or suspected allergy to insulin glargine or insulin aspart\n\n          -  Continuous parenteral nutrition\n\n          -  Participation in another trial which can influence the software algorithm"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932775", 
            "org_study_id": "ClinDiab-04"
        }, 
        "intervention": {
            "arm_group_label": "GlucoTab System", 
            "intervention_name": "GlucoTab System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University of Graz"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open, Single-centre, Non-controlled Study of Efficacy, Safety and Usability of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards", 
        "overall_official": {
            "affiliation": "Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism", 
            "last_name": "Thomas R Pieber, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime glucose values measured \u2265 24 hours after start of therapy", 
            "safety_issue": "Yes", 
            "time_frame": "duration of hospital stay (maximum three weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of blood glucose measurements per day", 
                "safety_issue": "Yes", 
                "time_frame": "duration of hospital stay (maximum three weeks)"
            }, 
            {
                "measure": "Adherence to the insulin dose suggestion of the GlucoTab system", 
                "safety_issue": "No", 
                "time_frame": "duration of hospital stay (maximum three weeks)"
            }, 
            {
                "measure": "Mean daily blood glucose as calculated by premeal and bedtime blood glucose values: Overall and per treatment day", 
                "safety_issue": "No", 
                "time_frame": "duration of hospital stay (maximum three weeks)"
            }
        ], 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}